Sobi receives orphan drug designation for Elocta in Switzerland
Advertisement
Swedish Orphan Biovitrum AB has received Orphan Drug Designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.
Haemophilia is an inherited condition that influences the blood's ability to clot. The most common type of the condition is haemophilia A, where people lack clotting factor FVIII. The symptoms can be mild to severe, depending on the level of clotting factor. People with haemophilia bleed for longer than usual and in severe haemophilia, internal bleeding around joints and muscles are frequent. This causes pain, stiffness and may lead to joint damage. Haemophilia A is a rare disease, occuring in 1 of 5.000 male births.
Other news from the department research and development
Most read news
More news from our other portals
Last viewed contents
Bavarian biotechnology maintains its position in the crisis and continues to grow - Strong start-up momentum, newly established companies above the national average
World first: Launch of Quebec registry for users of medical cannabis - MUHC researcher heads one of the largest studies ever conducted on medical cannabis
Implant-based cancer vaccine is first to eliminate tumors in mice - New approach reprograms the mammalian immune system to attack tumors body-wide
Study IDs link between sugar signaling and regulation of oil production in plants
It all adds up: Study finds forever chemicals are more toxic as mixtures - Research also finds that PFOA and PFOS are major contributors to toxicity
Affibody to publish data on therapeutic effects of Affibody molecules in a cancer model
‘Seaweed drug’ helps fight off infection - Alginates found in seaweed can combat multi-drug resistant infections
Antibiotic-releasing polymer may help eradicate joint implant infection
Unraveling the genome in 3D-space - Groundbreaking method to map contact points between replicated DNA molecules, thereby elucidating how the genome is folded inside the nucleus of human cells
European Molecular Biology Organization (EMBO) - Heidelberg, Germany
Software revolution for clinical trials - Health Tech Start-up Carelane Raises €800,000 in Pre-Seed Funding
